Detalhe da pesquisa
1.
Intra- and Interlaboratory Reproducibility of the Sensitivity to Endocrine Therapy Assay for Stage II/III Breast Cancer.
Clin Chem
; 67(9): 1240-1248, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34374711
2.
Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience.
Oncologist
; 25(11): e1803-e1806, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32949172
3.
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Lancet
; 389(10075): 1195-1205, 2017 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28215665
4.
Down's Syndrome and Triple Negative Breast Cancer: A Rare Occurrence of Distinctive Clinical Relationship.
Int J Mol Sci
; 18(6)2017 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28590426
5.
Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Cancer
; 122(17): 2654-62, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27284958
6.
Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy.
Curr Opin Oncol
; 28(6): 461-468, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27606693
7.
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
Breast Cancer Res Treat
; 154(3): 543-55, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26590813
8.
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Breast Cancer Res Treat
; 151(2): 373-84, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25935582
9.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
Lancet
; 382(9897): 1021-8, 2013 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-23871490
10.
Wnt signaling in triple negative breast cancer is associated with metastasis.
BMC Cancer
; 13: 537, 2013 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24209998
11.
Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy.
Am J Pathol
; 179(1): 46-54, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21703393
12.
Promise of Precision Medicine in Cancers: Lessons Learned.
S D Med
; 70(11): 486-490, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29088519
13.
Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls.
Lancet Oncol
; 12(3): 286-95, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21376291
14.
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.
Lancet Oncol
; 12(12): 1162-8, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21684810
15.
A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer.
Cancer Med
; 11(14): 2790-2800, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35307972
16.
A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacy.
Am J Cancer Res
; 11(6): 2867-2892, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34249433
17.
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study.
Genome Med
; 13(1): 155, 2021 10 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34607609
18.
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
JAMA Oncol
; 7(11): 1654-1663, 2021 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529000
19.
Hand-held spectroscopic device for in vivo and intraoperative tumor detection: contrast enhancement, detection sensitivity, and tissue penetration.
Anal Chem
; 82(21): 9058-65, 2010 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20925393
20.
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial.
Clin Cancer Res
; 26(8): 1896-1904, 2020 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31932495